Is it possible to buy Genius Sports Limited(GENI) shares at a good price now?

While Genius Sports Limited has overperformed by 3.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GENI rose by 43.24%, with highs and lows ranging from $12.45 to $6.37, whereas the simple moving average jumped by 29.70% in the last 200 days.

On July 25, 2025, Northland Capital started tracking Genius Sports Limited (NYSE: GENI) recommending Outperform. A report published by Arete on July 09, 2025, Initiated its previous ‘Buy’ rating for GENI. Truist also rated GENI shares as ‘Buy’, setting a target price of $14 on the company’s shares in an initiating report dated July 01, 2025. BTIG Research Reiterated the rating as Buy on April 22, 2025, but set its price target from $11 to $12. Deutsche Bank initiated its ‘Buy’ rating for GENI, as published in its report on April 21, 2025. Guggenheim also rated the stock as ‘Buy’.

Analysis of Genius Sports Limited (GENI)

Further, the quarter-over-quarter increase in sales is 24.38%, showing a positive trend in the upcoming months.

There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Genius Sports Limited’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -12.24% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.35, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

As an indicator of volatility for any stock, average volume can also be very valuable, and GENI is recording an average volume of 5.34M. On a monthly basis, the volatility of the stock is set at 5.33%, whereas on a weekly basis, it is put at 6.45%, with a gain of 6.08% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.39, showing growth from the present price of $12.39, which can serve as yet another indication of whether GENI is worth investing in or should be passed over.

How Do You Analyze Genius Sports Limited Shares?

Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.20%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.73% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

Hot this week

Procept BioRobotics Corp (PRCT)’s stock chart: A technical perspective

While Procept BioRobotics Corp has underperformed by -1.13%, investors...

Chewy Inc (CHWY)’s stock performance: a year in review

While Chewy Inc has overperformed by 2.45%, investors are...

Arcus Biosciences Inc (RCUS)’s stock price in review: A technical analysis

While Arcus Biosciences Inc has overperformed by 0.47%, investors...

A closer look at Edgewell Personal Care Co (EPC)’s stock price trends

While Edgewell Personal Care Co has overperformed by 0.51%,...

Arrowhead Pharmaceuticals Inc (ARWR)’s stock rises to 22.34 per share

While Arrowhead Pharmaceuticals Inc has overperformed by 2.52%, investors...

Topics

Procept BioRobotics Corp (PRCT)’s stock chart: A technical perspective

While Procept BioRobotics Corp has underperformed by -1.13%, investors...

Chewy Inc (CHWY)’s stock performance: a year in review

While Chewy Inc has overperformed by 2.45%, investors are...

Arcus Biosciences Inc (RCUS)’s stock price in review: A technical analysis

While Arcus Biosciences Inc has overperformed by 0.47%, investors...

A closer look at Edgewell Personal Care Co (EPC)’s stock price trends

While Edgewell Personal Care Co has overperformed by 0.51%,...

Arrowhead Pharmaceuticals Inc (ARWR)’s stock rises to 22.34 per share

While Arrowhead Pharmaceuticals Inc has overperformed by 2.52%, investors...

Yext Inc (YEXT) stock analysis: A comprehensive overview

While Yext Inc has overperformed by 0.22%, investors are...

Zevra Therapeutics Inc (ZVRA)’s stock price range in the last year

While Zevra Therapeutics Inc has underperformed by -0.64%, investors...

Kontoor Brands Inc (KTB) stock: A year of ups and downs

While Kontoor Brands Inc has underperformed by -1.58%, investors...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.